Investment Rating - The investment rating for the company is "Buy" and is maintained [9] Core Views - The company's performance meets expectations, with a recovery in sales of life science products. In 2024, the company achieved revenue of 559 million yuan, a year-on-year increase of 20.63%. The net profit attributable to shareholders was 72.19 million yuan, up 107.51% year-on-year [6][12] - The sales growth is primarily driven by stable industry demand and stable product prices, leading to a good increase in sales volume of life science products [2][13] - The company is actively expanding its overseas market, with overseas revenue reaching 351 million yuan in 2024, accounting for approximately 66.13% of total revenue, a year-on-year increase of 23.50% [13] - The company has a strong focus on R&D innovation, continuously launching new products, including cell culture series and liquid handling series, with sales of cell factory products growing approximately 28.55% year-on-year in 2024 [13] Summary by Sections Financial Performance - In 2024, the company reported total revenue of 559 million yuan, with biological culture business revenue of 172 million yuan (up 9.08%), liquid handling business revenue of 337 million yuan (up 22.64%), and instrument and other business revenue of 22.6 million yuan (up 28.27%) [2][6] - For Q1 2025, the company achieved revenue of 124 million yuan, a year-on-year increase of 26.00%, and a net profit of 16.46 million yuan, up 101.29% year-on-year [6] Profitability - The company's gross margin for 2024 was 41.41%, an increase of 10.79 percentage points year-on-year, while the net margin was 12.92%, up 5.41 percentage points year-on-year [13] Market Expansion - The overseas sales of the company's own brand increased by approximately 46.07% year-on-year, with the proportion of overseas self-owned brand revenue rising from about 15.98% to 18.89% [13] R&D and Product Development - The company is developing a range of new products, including various membrane products, with a focus on enhancing its product offerings in the life sciences sector [13]

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on revenue growth and profitability recovery. Core Insights - The company achieved a revenue of 559 million yuan in 2024, representing a year-over-year increase of 20.63%, with a net profit of 72 million yuan, up 107.51% year-over-year [1][2] - The growth in revenue is attributed to the successful promotion of its overseas self-owned brands and the overall growth in its life sciences product business [2] - The gross profit margin improved to 41.41% in 2024, an increase of 10.79 percentage points year-over-year, indicating a recovery in profitability [2] - The company is expected to continue its growth trajectory with projected revenues of 682 million yuan, 827 million yuan, and 992 million yuan for 2025, 2026, and 2027, respectively, with corresponding net profits of 99 million yuan, 122 million yuan, and 150 million yuan [2][3] Summary by Sections Financial Performance - In 2024, the company reported total revenue of 559 million yuan, a 20.63% increase from 2023, and a net profit of 72 million yuan, reflecting a 107.51% increase year-over-year [3] - The gross margin for 2024 was 41.41%, up from 30.6% in 2023, indicating improved cost management and pricing stability [3] Revenue Breakdown - The revenue from biological culture products reached 172 million yuan, growing by 9.08% year-over-year, while liquid handling products generated 337 million yuan, up 22.64% [2] - International sales accounted for 351 million yuan, a 23.50% increase, with overseas self-owned brand revenue rising by 46.07% [2] Future Projections - The company forecasts revenue growth of 22.2% in 2025, 21.1% in 2026, and 20.0% in 2027, with net profit growth rates of 37.4%, 22.7%, and 23.3% respectively [2][3]

证券代码：688026 证券简称：洁特生物 公告编号：2025-009 转债代码：118010 转债简称：洁特转债 3、预计实现归属于母公司所有者的扣除非经常性损益的净利润1,350万元，与上年同期（法定披露数 据）相比，增加926.17万元，同比增加218.52%。 广州洁特生物过滤股份有限公司 2025年第一季度业绩预告的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年3月31日。 （二）业绩预告情况 经公司财务部门初步测算，公司2025年第一季度： 1、预计实现营业收入12,300万元，与上年同期（法定披露数据）相比，增加2,472.47万元，同比增加 25.16%。 2、预计实现归属于母公司所有者的净利润1,400万元，与上年同期（法定披露数据）相比，增加582.15 万元，同比增加71.18%。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 2024年第一季度，公司业绩情况如下： 营业收入：9,827 ...